24 related articles for article (PubMed ID: 38688833)
1. Oncolytic virotherapy promotes radiosensitivity in soft tissue sarcoma by suppressing anti-apoptotic MCL1 expression.
Omori T; Tazawa H; Yamakawa Y; Osaki S; Hasei J; Sugiu K; Komatsubara T; Fujiwara T; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
PLoS One; 2021; 16(4):e0250643. PubMed ID: 33886686
[TBL] [Abstract][Full Text] [Related]
2. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer.
Sakai R; Kagawa S; Yamasaki Y; Kojima T; Uno F; Hashimoto Y; Watanabe Y; Urata Y; Tanaka N; Fujiwara T
Mol Cancer Ther; 2010 Jun; 9(6):1884-93. PubMed ID: 20501801
[TBL] [Abstract][Full Text] [Related]
4. Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells.
Hasei J; Sasaki T; Tazawa H; Osaki S; Yamakawa Y; Kunisada T; Yoshida A; Hashimoto Y; Onishi T; Uno F; Kagawa S; Urata Y; Ozaki T; Fujiwara T
Mol Cancer Ther; 2013 Mar; 12(3):314-25. PubMed ID: 23315976
[TBL] [Abstract][Full Text] [Related]
5. Bone and Soft-Tissue Sarcoma: A New Target for Telomerase-Specific Oncolytic Virotherapy.
Tazawa H; Hasei J; Yano S; Kagawa S; Ozaki T; Fujiwara T
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32085583
[TBL] [Abstract][Full Text] [Related]
6. Real-Time Fluorescence Image-Guided Oncolytic Virotherapy for Precise Cancer Treatment.
Yano S; Tazawa H; Kishimoto H; Kagawa S; Fujiwara T; Hoffman RM
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477279
[TBL] [Abstract][Full Text] [Related]
7. [Theranostic application of telomerase-specific oncolytic adenovirus for human cancer].
Fujiwara T; Tanaka N
Nihon Rinsho; 2007 Oct; 65(10):1913-22. PubMed ID: 17926546
[TBL] [Abstract][Full Text] [Related]
8. [Oncolytic virotherapy for human solid tumors].
Fujiwara T
Gan To Kagaku Ryoho; 2009 May; 36(5):703-9. PubMed ID: 19461167
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic adenovirus-induced autophagy: tumor-suppressive effect and molecular basis.
Tazawa H; Kagawa S; Fujiwara T
Acta Med Okayama; 2013; 67(6):333-42. PubMed ID: 24356717
[TBL] [Abstract][Full Text] [Related]
10. p53-Armed Oncolytic Virotherapy Improves Radiosensitivity in Soft-Tissue Sarcoma by Suppressing BCL-xL Expression.
Komatsubara T; Tazawa H; Hasei J; Omori T; Sugiu K; Mochizuki Y; Demiya K; Yoshida A; Fujiwara T; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Acta Med Okayama; 2024 Apr; 78(2):151-161. PubMed ID: 38688833
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]